{"entity":{"id":"nct04686682","kind":"trial","name":"A First-in-Human, JAB-8263 in Adult Patients With Advanced Tumors","aka":[],"tldr":"A phase 1/2 trial of JAB-8263 in non-small-cell lung cancer, small-cell lung cancer and ovarian cancer, run by Jacobio Pharmaceuticals Co., Ltd., now recruiting.","summary":"A First-in-Human, JAB-8263 in Adult Patients With Advanced Tumors is a phase 1/2 interventional study registered as NCT04686682 by Jacobio Pharmaceuticals Co., Ltd., with 152 participants planned, started 2021-05-07 and due to reach its primary completion in 2028-01. Interventions recorded: JAB-8263.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT04686682","url":"https://clinicaltrials.gov/study/NCT04686682"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["nsclc","sclc","ovarian"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT04686682","phase":"1/2","setting":"A Phase I/IIa, Multi-Center, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Evidence of Antitumor Activity of JAB-8263 in Adult Patients With Advanced Malignant Tumors","sponsor":"Jacobio Pharmaceuticals Co., Ltd.","enrolled":152,"outcomes":[]},"route":"/trials/nct04686682/","neighbours":{"cancer":[{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"},{"id":"ovarian","kind":"cancer","name":"Ovarian cancer","route":"/cancers/ovarian/"},{"id":"sclc","kind":"cancer","name":"Small-cell lung cancer","route":"/cancers/sclc/"}],"company":[{"id":"jacobio-pharmaceuticals","kind":"company","name":"Jacobio Pharmaceuticals","route":"/companies/jacobio-pharmaceuticals/"}]}}